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With a very low survival rate, pancreatic ductal adenocarcinoma (PDAC) is a deadly
disease. This has been primarily attributed to (i) its late diagnosis and (ii) its high
resistance to current treatment methods. The latter specifically requires the development
of robust, realistic in vitro models of PDAC, capable of accurately mimicking the in vivo
tumor niche. Advancements in the field of tissue engineering (TE) have helped the
development of such models for PDAC. Herein, we report for the first time a novel
hybrid, polyurethane (PU) scaffold-based, long-term, multicellular (tri-culture) model of
pancreatic cancer involving cancer cells, endothelial cells, and stellate cells. Recognizing
the importance of ECM proteins for optimal growth of different cell types, the model
consists of two different zones/compartments: an inner tumor compartment consisting
of cancer cells [fibronectin (FN)-coated] and a surrounding stromal compartment
consisting of stellate and endothelial cells [collagen I (COL)-coated]. Our developed
novel hybrid, tri-culture model supports the proliferation of all different cell types for
35 days (5 weeks), which is the longest reported timeframe in vitro. Furthermore, the
hybrid model showed extensive COL production by the cells, mimicking desmoplasia,
one of PDAC’s hallmark features. Fibril alignment of the stellate cells was observed,
which attested to their activated state. All three cell types expressed various cell-
specific markers within the scaffolds, throughout the culture period and showed
cellular migration between the two zones of the hybrid scaffold. Our novel model
has great potential as a low-cost tool for in vitro studies of PDAC, as well as for
treatment screening.
Keywords: pancreatic cancer, multicellular tumor model, 3D model, endothelial cells, pancreatic stellate cells,
scaffold-assisted tumor model, polyurethane scaffold
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related deaths worldwide and accounts for about
7% of all cancer-related deaths (Siegel et al., 2018). The 5-year
survival rate is about 9% and has barely improved over the last
decades (Cancer.Net, 2019). These dismal figures for PDAC are
due to its late-stage diagnosis, early and rapid metastasis, along
with a high resistance to currently available treatment options
(mainly, chemotherapy and radiotherapy) (Kleeff et al., 2016).
The latter is attributed to the complex tumor microenvironment
(TME) of PDAC. The PDAC’s TME consists of a cocktail of
cellular, biochemical, biomechanical, and structural components,
which interact in complex ways and contribute to the disease
progression. More specifically, the stellate cells of the TME
are known to produce very high amounts of extracellular
matrix (ECM) proteins, leading to the so-called desmoplastic or
fibrotic reaction. The increase of matrix proteins, e.g., collagen,
fibronectin (FN), also results in tumor vessel collapse, along with
the formation of aberrant, disorganized vessel networks (Longo
et al., 2016). Overall, fibrosis/desmoplasia contributes to the high
resistance of PDAC to treatment (Seicean et al., 2015; Chand et al.,
2016; Totti et al., 2017; Ansari et al., 2018; Totti et al., 2018).
Traditionally, research on PDAC is conducted in (i) 2D in vitro
systems (Onishi et al., 2012; Sato et al., 2018; Zhang et al.,
2018; Serri et al., 2019) or in (ii) animal models, primarily
mice (Awasthi et al., 2011; Dovzhanskiy et al., 2012; Courtin
et al., 2013; Shinoda et al., 2018; Zhang et al., 2018; Awasthi
et al., 2019). Although 2D systems are cheap, easy to use,
and reproducible, they are unable to mimic accurately key
in vivo characteristics like the TME structure, stiffness, the
cellular spatial orientation, the cellular cross-talk, the cell-ECM
interactions, or the environmental gradients (Onishi et al., 2012;
Adcock et al., 2015; Jaidev et al., 2015; Totti et al., 2017; Chim and
Mikos, 2018). Animal models can accurately mimic the in vivo
conditions and hence are widely used for laboratory research and
pre-clinical trials (Pérez–Mancera et al., 2012; Courtin et al., 2013;
Bermejo-Rodríguez and Pérez-Mancera, 2015; Erstad et al., 2018;
Humpton et al., 2019; Yan et al., 2019). However, such systems
are expensive, difficult to use, and are not easily reproducible
(Pérez–Mancera et al., 2012; Adcock et al., 2015; Ireland et al.,
2016; Yan et al., 2019).
Advancements in the field of tissue engineering (TE) have
enabled the development of different types of 3D in vitro
models that realistically mimic in vivo tissue niches, including
tumor tissues. Current 3D models of pancreatic tumors include
(i) spheroids (from cell lines) or organoids (from primary
tissue) (Froeling et al., 2009; Matsuda et al., 2010; Longati
et al., 2013; Wen et al., 2013; Boj et al., 2015; Chiellini et al.,
2016; Di Maggio et al., 2016; Ware et al., 2016; Brancato
et al., 2017), (ii) hydrogels (Ki et al., 2014; Chiellini et al.,
2016; Brancato et al., 2017; Okumura et al., 2019), and (iii)
polymeric scaffolds based systems (He et al., 2013; Raza et al.,
2013; Wang et al., 2013; Ricci et al., 2014; Chand et al., 2016;
Totti et al., 2018). Overall, such 3D models have substantial
advantages as compared to 2D systems and animal models.
These include low cost and higher reproducibility, as compared
to animal models and provision of more realistic structure,
cell–cell and cell–ECM interactions, and realistic distribution
of parameters, such as nutrients and oxygen concentration,
as compared to 2D systems (Fernandes et al., 2009; Wang
et al., 2016; Totti et al., 2017). For example, Longati et al.
(2013) showed increased matrix protein secretion and increased
resistance to the chemotherapeutic agent Gemcitabine in 3D
spheroids, as compared to 2D systems for PANC-1 pancreatic
cancer cell lines. Similarly, an increase in chemo-resistance in
3D spheroids when compared to 2D was also reported by
Wen et al. (2013) for PANC-1 and MIA PaCa-2 cell lines. Ki
et al. (2014) encapsulated COLO-357 cells within poly(ethylene
glycol)-based hydrogels enhanced with collagen I (COL) fibrils
to mimic the PDAC’s desmoplasia and observed enhanced
cell proliferation and epithelial–mesenchymal transition (EMT)
within gels enriched with COL. Long-term (i.e., some weeks),
culture of pancreatic cancer cells within polymeric scaffolds and
hydrogels has been reported in some studies (Ricci et al., 2014;
Chiellini et al., 2016; Totti et al., 2018; Gupta et al., 2019).
Chiellini et al. carried out long-term (28 days) culture of BxPC-
3 cell lines within micro-structured chitosan (mCS)-based or
polyelectrolyte complex (mPEC) hydrogels. It was reported that
cells in the hydrogels were able to maintain cancer features, like
loss of cell polarity, which were not present in 2D. Furthermore,
increase in matrix stiffness enhanced the expression of tumor-
specific markers (Chiellini et al., 2016). We have also recently
reported long-term (more than 5 weeks) culture of various PDAC
cell lines, i.e., PANC-1, AsPC-1, BxPC-3, in polyurethane (PU)
polymeric scaffolds wherein cell clustering, cell proliferation, and
matrix protein production followed in vivo-like trends (Totti
et al., 2018). We also reported that the model was able to mimic
a clinically relevant response to various treatment protocols
(Gupta et al., 2019).
However, all of the above models are monocellular, taking into
consideration only pancreatic cancer cells. Therefore, they cannot
recapitulate accurately the cellular complexity of the PDAC TME,
which contains a plethora of different cell types, e.g., endothelial
cells, stellate cells, which are crucial for the disease progression
and resistance to treatment (Wehr et al., 2011; Hamada et al.,
2012; Karnevi et al., 2016; Bynigeri et al., 2017). It is therefore
important to recapitulate, in addition to the structural and
biochemical complexity, features of the biological complexity of
the PDAC TME. There are very limited multicellular 3D PDAC
models, such as spheroids/organoids or hydrogel-based systems
(Froeling et al., 2009; Di Maggio et al., 2016; Longo et al.,
2016; Priwitaningrum et al., 2016; Ware et al., 2016; Brancato
et al., 2017; Kuen et al., 2017; Noel et al., 2017; Shoval et al.,
2017; Lazzari et al., 2018). Most multicellular PDAC models
consist of two cells types involving cancer cells co-cultured with
fibroblasts/stellate cells, endothelial cells, mesenchymal stem cells
(MSCs), or immune cells. For example, Froeling et al. used
COL and Matrigel to create spheroids of pancreatic cancer cells
(Capan-1 and PaCa-3) with activated stellate cells or the normal
fibroblastic cell line MRC-5 for 7 days. An increase in the number
of invasive cancer cells and a decrease in the expression of
cytokeratin (suggesting EMT) was observed in presence of stellate
cells and MRC-5 fibroblasts (Froeling et al., 2009). Similarly,
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Drifka et al. employed a collagen-coated microchannel spheroid-
based co-culture of cancer cells (PANC-1) and primary stellate
cells. Stellate cells facilitated collagen fiber alignment and helped
cancer cell migration through the matrix (Drifka et al., 2016).
Kuen et al. showed that the co-culture of cancer cells (PaTu-
8902, BxPC-3, HPAC, and MiaCaPa-2) and MRC-5 fibroblasts in
a spheroid model induced the production of immunosuppressive
cytokines, highlighting the immunosuppressive role of different
cell types within the tumor niche (Kuen et al., 2017). Ware et al.
(2016) observed an impaired diffusion of Gemcitabine (1000 µM)
in PDAC spheroids (PANC-1, AsPC-1, BxPC-3, Capan-1, and
MIA PaCa-2) when they contained primary stellate cells as
compared to mono-cellular cancer cell spheroids. Similarly,
an increased resistance to oxaliplatin treatment in co-culture
of patient-derived cancer associated fibroblasts (CAFs) with
pancreatic cancer cells (MIA PaCa-2 and AsPC-1) in spheroids
was observed by Broekgaarden et al. (2019). There are very few
studies reporting co-culture of cancer cells with endothelial cells.
Shoval et al. (2017) performed a 72-h co-culture with BxPC-
3 PDAC cells and endothelial cells (HUVECs) in a spheroid
model, wherein it was shown that the HUVECs mainly grew at
the periphery of the spheroids and were unable to form vascular
structures within the spheroids.
Among the multicellular PDAC studies, there are very limited
studies of PDAC involving the presence of three cell types, and
all those studies are in spheroid-type systems for a relatively
short time period (24 h to 7 days). For example Beckermann
et al. (2008) co-cultured pancreatic cancer cells (Capan-1, MIA-
PaCa2, COLO-357, and BxPC-3), endothelial cells (HUVECs),
and normal primary fibroblast cells in a spheroid model for 24 h.
Di Maggio et al. (2016) developed a spheroid (Matrigel and COL-
assisted)-based tri-culture model involving cancer cells (Capan-1,
COLO-357, and AsPC-1), HUVECs, and activated pancreatic
stellate cells (PS-1) and cultured it for 7 days. A gradual depletion
of CD-31 positive HUVECs was observed in the spheroid
system over time. Similarly, Lazzari et al. developed a co-culture
model, which included cancer cells (PANC-1), HUVECs, and the
fibroblast cell line MRC-5 for a period of 7 days. No endothelial
cells were observed in the system after 4 days in culture.
Furthermore, higher resistance to gemcitabine and doxorubicin
was observed in the multicellular spheroids as compared to the
monocellular ones (Lazzari et al., 2018).
Overall, spheroid-type multicellular models are valuable and
suitable for molecular analysis and for fast drug response studies;
however, they have certain limitations. Due to their spatial
characteristics, artificially high diffusion gradients in terms of
nutrients and oxygen can be formed, resulting in necrotic cores
at the center and decreasing cellular proliferation very quickly
(within a few days) (Burdett et al., 2010; Nath and Devi, 2016;
Totti et al., 2017). Consequently, they are difficult to maintain
over a long period of time (weeks or months) without re-
suspending the cells to form fresh cellular aggregates. Such re-
suspension can disturb the formed TME and cell–cell, cell–ECM
interactions. Furthermore, it is difficult to robustly control the
spheroid size and shape (Burdett et al., 2010; Nath and Devi, 2016;
Totti et al., 2017). Hydrogel-type spheroids have better structure
than simple cell-aggregates; however, they have relatively weak
mechanical strength, making their long-term maintenance in
culture challenging (Hoffman, 2012; Totti et al., 2017).
Polymer scaffold-assisted 3D structures can overcome several
of the limitations associated with spheroids and hydrogels. They
can provide a more robust mechanical strength and tunability
allowing for much longer cultures (up to months), and they
can be tuned to have appropriate internal structure, pore size,
type, and distribution, enabling the recapitulation of the spatial
organization of different cell types in a multicellular system,
as well as allowing for proper diffusion of oxygen and other
nutrients (O’Brien, 2011; Ricci et al., 2014; Velliou et al.,
2015; Totti et al., 2017, 2018; Gupta et al., 2019). To the
best of our knowledge, to date, there is no scaffold-assisted,
multicellular model for PDAC.
The aim of this work was to address the above challenge via the
development of a novel, multicellular, hybrid, PU scaffold-based
model involving PANC-1 cancer cells, human microvascular
endothelial cells (HMECs), and PS-1 pancreatic stellate cells.
More specifically, building on our previously developed
monocellular PU scaffold (Totti et al., 2018; Gupta et al., 2019),
we performed appropriate zonal surface modification of the
scaffolds with FN or COL to support growth and proliferation of
different cells of the PDAC TME and we monitored proliferation,
spatial organization, ECM secretion, and cellular interactions for
a total of 5 weeks.
MATERIALS AND METHODS
Polymer Scaffold Preparation and
Surface Modification
Polyurethane scaffolds were fabricated via the thermal induced
phase separation method, as reported previously (Velliou et al.,
2015; Totti et al., 2018). The scaffolds were then cut at appropriate
sizes (see sections “Single Scaffold-Based 3D Cell Culture”
and “Scaffold-Based Zonal 3D Cell Culture”) and sterilized by
exposing them to 70% ethanol (3 h) and UV ray (1 h). As
previously reported, the average pore size of the scaffolds was
100–150 µm, the porosity was 85–90%, and the elastic modulus,
20 ± 2 kPa. It should be stated that the stiffness of the scaffolds
was similar to that of PDAC ex vivo tissue (Chantarojanasiri and
Kongkam, 2017; Pozzi et al., 2017; Rice et al., 2017).
Thereafter, as previously described, the generated scaffolds
were surface modified (adsorption) with FN or COL for ECM
mimicry (Totti et al., 2018; Gupta et al., 2019).
2D Cell Culture
The human pancreatic adenocarcinoma cell line PANC-1
(Sigma–Aldrich, Merck, United Kingdom) was expanded
in Dulbecco’s modified Eagle’s medium (DMEM) with
high glucose (Sigma–Aldrich, Merck, United Kingdom)
supplemented with 10% fetal bovine serum (FBS, Fisher
Scientific, United Kingdom), 1% penicillin/streptomycin (Fisher
Scientific, United Kingdom), and 2 mM L-glutamine (Sigma–
Aldrich, Merck, United Kingdom) in a humidified incubator at
37◦C with 5% CO2.
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The HMEC line CRL-3243 (ATCC, United Kingdom)
was expanded in MCDB 131 medium (GIBCO, Thermo
Fisher, United Kingdom), supplemented with 10% FBS,
1% penicillin/streptomycin, 2 mM L-glutamine, 10 ng/ml
epidermal growth factor (SIGMA–Aldrich, Merck,
United Kingdom), and 1 µg/ml hydrocortisone (SIGMA–
Aldrich, Merck, United Kingdom) in a humidified incubator at
37◦C with 5% CO2.
The immortalized human pancreatic stellate cells (PS-1)
were expanded in DMEM/F12 medium (GIBCO, Thermo
Fisher, United Kingdom) supplemented with 10% FBS, 1%
penicillin/streptomycin, and 2 mM L-glutamine in a humidified
incubator at 37◦C with 5% CO2.
All cells were passaged regularly on reaching 80–
90% confluency with TrypLE (GIBCO, Thermo Fisher,
United Kingdom) until the required cell densities were obtained.
3D Cell Culture
Single Scaffold-Based 3D Cell Culture
Uncoated, FN- or COL-coated scaffolds were tested to analyze
their ability to support PS-1 and HMEC cells in mono-culture,
co-culture (PANC-1 + HMEC or PANC-1 + PS-1), and tri-
culture (PANC-1+ PS-1+HMEC).
For mono-culture experiments, 0.5 × 106 cells were seeded
in each scaffold (5 × 5 × 5-mm3-sized) (re-suspended in a
total of 30 µl of cell culture media per scaffold) (Totti et al.,
2018; Gupta et al., 2019). For the co-culture and tri-culture
experiments, 0.25 × 106 cells per cell type were seeded in each
scaffold (5 × 5 × 5-mm3-sized), placed in 24 well plates, and
cultured for 28 days (4 weeks), as per our previously established
protocol (Totti et al., 2018; Gupta et al., 2019).
Scaffold-Based Zonal 3D Cell Culture
The single scaffold-based analysis for mono-, co-, and tri-cultures
showed that different cell types prefer different ECM presence
on the scaffold surface (see section “Results”). Therefore, to
recapitulate that, a zonal scaffold architecture was designed. More
specifically, as shown in Figure 1, two separate zones (a hollow
cuboid with dimensions of approximately 7 × 7 × 5 mm3 and
a solid inner cylinder of diameter of approximately 2 mm and
height of 5 mm) were created/cut from the PU scaffold (prepared
as described in section “Polymer Scaffold Preparation and Surface
Modification”) using a biopsy punch. The outer cuboid was
coated with COL, while the inner cylinder was coated with FN
through passive absorption, as described in Section “Polymer
Scaffold Preparation and Surface Modification.” HMEC and PS-1
stellate cells were seeded into the hollow cuboid in different ratios.
As previously described, immediately after seeding, the scaffolds
were placed in the incubator and cultured per our established
protocol (Totti et al., 2018; Gupta et al., 2019) (section “Single
Scaffold-Based 3D Cell Culture”). Based on our monocellular
studies (Figure 2; Totti et al., 2018), we observed that PANC-1
cancer cells expanded at a faster rate in comparison to PS-1 and
HMEC cells. Hence, to avoid the cancer cells’ over-growing, as
compared to the endothelial and stellate cells, we cultured the
supporting cells (PS-1 and HMEC) for 7 days. On day 7, PANC-
1 cells were seeded into the solid inner cylinder in a similar
manner and then plugged inside the hollow cuboid to assemble to
complete hybrid zonal model. The final ratios tested for PANC-
1: HMEC: PS-1 were 1:1:1, 1:2:2, and 1:2:9, based on both ratios
reported in literature for spheroid systems and on our initial
trials (see single-scaffold-based experiments in sections “Single
Scaffold-Based 3D Cell Culture” and “Scaffold-Based Zonal 3D
Cell Culture”) (Froeling et al., 2009; Di Maggio et al., 2016;
Lazzari et al., 2018). Thereafter, the tri-culture was monitored for
an additional 28 days (4 weeks). Separate inner and outer scaffold
compartments were also cultured for the same duration of the
experiment as controls for the individual zones.
Alamar Blue Viability Assay
The Alamar Blue assay was carried out every week per the
manufacturer’s instructions, to assess the cellular metabolic
activity of the 3D cultures. Briefly, 10% Alamar Blue (Thermo
Scientific, United Kingdom) solution was prepared in complete
cell culture medium and added to the scaffolds followed by 2–
3 h incubation at 37◦C. At the end of the incubation period,
change in Alamar Blue fluorescence was measured using BioTek,
Plate reader (BioTek, United Kingdom) at 530 nm excitation and
590 nm emission.
Immunofluorescence Assay
In situ immunofluorescence (IF) staining of the scaffolds took
place for the spatial determination of (i) the different cell
types, CD-31 (HMEC), αSMA (PS-1), and pan-Cytokeratin
(PANC-1), (ii) the cell proliferation (Ki-67), and (iii) the ECM
production (COL). More specifically, scaffolds were snap frozen
at specific time points in liquid nitrogen for 15 min and then
preserved at -80◦C until sectioning, as previously described
(Allenby et al., 2017, 2019; Tahlawi et al., 2019). Prior to IF
staining, scaffolds were sectioned and fixed for 4 h in 4% w/v
paraformaldehyde (Sigma–Aldrich, Merck, United Kingdom).
For intracellular proteins, scaffold sections were permeabilized
for 2 h with 0.1% Triton-X solution (Sigma–Aldrich, Merck,
United Kingdom), followed by 3 h blocking using 10% donkey
serum solution. For membrane associated proteins, blocking
was carried out without permeabilization. The primary antibody
staining was carried out overnight, followed by overnight
secondary antibody and DAPI co-staining. Each step employed
a solvent containing 1% w/v bovine serum albumin (Sigma–
Aldrich, Merck, United Kingdom) and 0.5% v/v Tween-20
(Promega, United Kingdom). For multi-panel staining involving
both cell membrane and intracellular proteins, blocking, primary,
secondary and DAPI staining solutions were made using 1% BSA,
0.5% Tween-20, and 0.1% Saponin (SIGMA–Aldrich, Merck,
United Kingdom) solution to facilitate gentle permeabilization
without the use of Triton-X.
Confocal Laser Scanning Microscopy
(CLSM) Imaging
Immunofluorescent samples were imaged with a Nikon Ti-
Eclipse inverted confocal microscope (Nikon Instruments,
Europe) and processed with the NIS-Elements software using the
following lasers and filters: (i) 405 (for DAPI), (ii) 488 (for Alexa
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FIGURE 1 | Schematic diagram of the zonal architecture development for the scaffold-assisted multicellular model of PDAC. Polyurethane (PU) scaffolds were
appropriately cut to design the zonal architecture. Different cells types were seeded at different time points and at different locations of the scaffold. The tri-culture
system was monitored for 28 days (for a total experimental period of 35 days).
FIGURE 2 | Overall cellular metabolic activity as determined by the Alamar Blue metabolic assay within different PU scaffolds configurations (uncoated-PU,
fibronectin-FN-coated, and collagen-COL-coated). (A) HMEC. (B) PS-1. *p ≤ 0.05, **p ≤ 0.01.
Fluor 488, Dylight 488), (iii) 561 (for Alexa Fluor 555, Dylight
550), and (iv) 643 nm (for Alexa Fluor 647, Dylight 650) for two
sequential scans. Confocal images were captured using a 10x dry
objective, with a 512× 512-pixel resolution and 5–10 µm Z-stack
distance, as previously described (Totti et al., 2018; Gupta et al.,
2019). Multiple scaffolds as well as multiple areas and sections per
scaffold were imaged to ensure reproducibility. Representative
images are presented in this manuscript.
Statistical Analysis
Statistical analysis was performed for at least three independent
experiments (n ≥ 3) with at least three replicates per time
point. Analysis of variance (ANOVA), followed by the Tukey’s
multiple comparison test, using the Graph Pad Prism R© software
(version 8.00 for Windows) to determine data statistical
significance (p < 0.05). The error bars in the graphs represent
standard error of mean.
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RESULTS
Long-Term Mono-Culture of Stellate
Cells and Endothelial Cells on PU
Scaffolds
We have previously reported that PANC-1 pancreatic cancer cells
are able to grow on PU scaffolds for over 28 days (4 weeks),
forming dense cell clusters and secreting substantial amounts of
COL in FN coated scaffolds (Totti et al., 2018). Similarly, in this
work, mono-cultures of HMEC endothelial cells and PS-1 stellate
cells were established on PU scaffolds both uncoated and coated
with either FN or COL for 28 days (section “Single Scaffold-
Based 3D Cell Culture”). Cell growth and viability were assessed
weekly using the Alamar Blue viability assay (section “Alamar
Blue Viability Assay”). As observed in Figure 2, both HMEC and
PS-1 cells were able to attach and grow on the PU scaffolds for
28 days. At the end of 28 days, HMEC showed significantly higher
cell viability on COL-coated scaffolds in comparison to uncoated
ones. PS-1 stellate cells showed a significantly higher preference
for coated scaffolds (FN or COL) over uncoated ones in terms
of cellular metabolic activity as measured by the Alamar Blue
assay (Figure 2).
Single PU Scaffold-Based Co-Culture
and Tri-Culture of Stellate (PS-1),
Endothelial (HMEC), and Cancer Cells
(PANC-1)
As observed in the mono-culture experimental systems (section
“Long-Term Monoculture of Stellate Cells and Endothelial Cells
on PU Scaffolds”), both the PS-1 and HMEC cells were able to
grow on PU scaffolds for 28 days and showed a preference for
ECM protein coated scaffolds in comparison to those uncoated
(Figure 2). Also, in our previously published work (Totti et al.,
2018), we have reported that PANC-1 cells were able to grow on
PU scaffolds (both coated and uncoated) for 28 days (4 weeks),
with higher proliferation being observed in FN-coated scaffolds.
Therefore, based on the results of the mono-cultures, we
established co-culture and tri-culture systems using PU scaffolds,
either uncoated or coated (FN or COL). Protein coatings enable
the determination of the effects of different ECM proteins on such
complex multicellular 3D models. As described in section “Single
Scaffold-Based 3D Cell Culture,” different combinations of the
three cell types (PANC-1+HMEC, PANC-1+ PS-1, and PANC-
1 + HMEC + PS-1) were added to the scaffolds and cultured for
28 days. The overall cellular metabolic activity as an indication of
the overall cell viability was monitored at regular intervals via the
Alamar Blue Viability Assay (Figure 3).
As can be seen in Figure 3, the co-cultures as well as the
tri-culture involving PANC-1, PS-1, and HMEC cells were all
viable throughout the duration of our experiment (28 days).
Significantly higher number of viable cells were observed on
PU scaffolds coated with FN or COL in comparison to the
uncoated scaffolds, similar to the HMEC and PS-1 mono-
cultures (Figure 2; section “Long-Term Monoculture of Stellate
Cells and Endothelial Cells on PU Scaffolds”), as well as in
comparison to our previously published work for cancer cells
(PANC-1) mono-culture (Totti et al., 2018). At the end of 28 days,
sectioning and in situ fluorescence imaging of different cell-
specific markers was conducted (i) to monitor the growth of
all different cell types and (ii) to enable the assessment of the
cell spatial distribution within the scaffolds (Figure 4). More
specifically, HMEC cells were identified by CD-31 marker, stellate
cells were identified by αSMA, and PANC-1 cells were stained
for pan-Cytokeratin (section “Immunofluorescence Assay”). It is
worth pointing out that most cancer cell lines are a heterogeneous
mixture of cells at different stages of differentiation, hence not
all cancer cells express the same proteins/markers (in this case,
pan-Cytokeratin). Therefore, for our confocal laser scanning
microscopy (CLSM) imaging in co and tri-culture systems, cells
that only showed DAPI (nucleus) staining and no cell specific
markers are assumed to be PANC-1 cancer cells.
As seen in Figure 4, all three cell types—i.e., cancer,
endothelial, and stellate cells—were present within the PU
scaffolds at the end of the 28-day culture period for both ECM
coatings. The growth rate though of different cell types varied
depending on the coating. For example, although FN-coated
scaffolds promoted the growth of all cell types (both in co- and
tri-culture systems, Figures 4A–C), for the co-culture of PANC-
1 cancer cells and PS-1 stellate cells, the growth of PANC-1 was
higher as compared to PS-1 cells (Figure 4A). More specifically,
the PS-1 stellate cells were mainly found toward the periphery
of the model, while PANC-1 cells were distributed throughout
the whole scaffold. In contrast, COL-coating helped in a more
homogenous growth and distribution of PS-1 stellate cells in
a PANC-1 and PS-1 co-culture system (Figure 4D). The co-
culture of PANC-1 cancer cells and HMEC endothelial cells also
showed a similar trend. FN-coated scaffolds promoted the growth
of PANC-1 over HMEC cells (Figure 4B), although in contrast
to PS-1 (Figure 4A), HMEC cells were more evenly distributed
within the FN-coated scaffolds (Figure 4B). COL-coating showed
a significant increase in the number of endothelial cells within
the scaffold resulting in dense cellular clusters (Figure 4E),
clearly highlighting HMEC cells’ preference for COL matrix
protein. Nonetheless, both FN- and COL-coating were able
to support a tri-culture tumor model within the PU scaffolds
(Figures 4C,F). Similar to the co-cultures (Figures 4A,B), FN-
coated PU scaffolds favored PANC-1 cancer cells over the HMEC
and PS-1 cells (Figure 4C). The growth of the stellate cells was
particularly suppressed within this system. In contrast, the COL-
coated scaffolds promoted the growth of HMEC and PS-1 cells,
resulting in a more homogenous distribution of all three cells
types within the tumor model (Figure 4F).
PU Scaffold-Based Hybrid Zonal
Multicellular Model of PDAC With
Tri-Culture of Stellate (PS-1), Endothelial
(HMEC), and Cancer Cells (PANC-1)
Overall, our observations on the co-culture and tri-culture
systems above [section “Single PU Scaffold-Based Co-Culture
and Tri-Culture of Stellate (PS-1), Endothelial (HMEC),
and Cancer Cells (PANC-1)”], highlighted that the cellular
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FIGURE 3 | Overall cellular metabolic activity as determined by the Alamar Blue metabolic assay within different PU scaffolds configurations (uncoated,
fibronectin-FN-coated, and collagen-COL-coated). (A) PANC-1 + HMEC. (B) PANC-1 + PS-1. (C) PANC-1 + HMEC + PS-1. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
FIGURE 4 | Representative immunofluorescence CLSM images of sections of the 3D scaffolds after 28 days (4 weeks) of culturing multiple cell types in
fibronectin-coated (A–C) and collagen I-coated (D–F) coated scaffolds: PANC-1 PDAC cell lines are in yellow (pan-Cytokeratin staining), PS-1 stellate cells are in
green (αSMA staining), and HMEC endothelial cells are in red/pink (CD-31 staining). All cells were stained with DAPI, as well (blue). Scale bar = 100 µm.
interactions and cellular growth rates of different cell types in
a mixed culture are affected by the ECM protein coating of the
PU scaffolds. Specifically, for our PDAC model, PANC-1 cancer
cells prefer FN coating, while the HMEC endothelial cells prefer
COL. PS-1 stellate cells prefer coated scaffolds, both FN and COL,
over uncoated ones. Thus, we further designed a hybrid zonal
PU scaffold-based model with different ECM-coatings (Figure 1).
More specifically, as described in Section “Scaffold-Based Zonal
3D Cell Culture,” PS-1 and HMEC cells were cultured in a COL-
coated external scaffold (stromal compartment), while PANC-1
was grown in an FN-coated inner scaffold (tumor compartment).
This configuration enabled (i) tailoring of the ECM to the
cell needs and (ii) a better zonal recapitulation of the cell
distribution in the PDAC TME. The zonal model was monitored
and analyzed at a compartmental level and as a whole (both
compartments). More specifically, the following compartments
were monitored: (i) FN-coated inner cylinder compartment
containing PANC-1 cancer cells, (ii) COL-coated outer cuboid
compartment containing HMEC and PS-1 cells, and (iii) the
complete hybrid model containing both the inner and the outer
compartment (see also section “Scaffold-Based Zonal 3D Cell
Culture” and Figure 1).
Fibronectin-Coated PU Inner Cylinder Compartment
of the Hybrid Scaffold (Containing PANC-1 Cells)
A mono-culture of PANC-1 cancer cells in the FN-coated inner
scaffold compartment was monitored for 28 days, since for our
hybrid model PANC-1 cancer cells were added 7 days after the
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development of the outer cuboid (see also Figure 1 and section
“Scaffold-Based Zonal 3D Cell Culture”). Cell proliferation (Ki-
67), secretion of ECM (i.e., human specific COL), and expression
of cell specific markers (pan-Cytokeratin and CD-24) were
assessed at regular intervals via immunostaining and CLSM
imaging [see also sections “Immunofluorescence Assay” and
“Confocal Laser Scanning Microscopy (CLSM) Imaging”].
As observed in Figure 5, Ki-67 positive proliferative cancer
cells were observed throughout the entire culture period (top
panel). Multiple PANC-1 cells within the scaffolds expressed both
pan-Cytokeratin and CD-24 cellular markers (Figure 5, middle
panels), highlighting the heterogeneous nature of the cancer
cell population for the PANC-1 cell line (Schüssler et al., 1992;
Aghamaliyev et al., 2015; Pei et al., 2016; Haeberle and Esposito,
2019). In vivo, COL is overexpressed by pancreatic tumor cells
(Imamura et al., 1995) and hence is considered to be an important
parameter for the development of a robust in vitro model of
PDAC. As observed, PANC-1 cells were able to secrete COL
within the FN-coated inner compartment of the hybrid scaffold
throughout the culture period, the amount increasing with time
FIGURE 5 | Representative immunofluorescence CLSM images of fibronectin-coated PU inner cylinder of the hybrid scaffold with PANC-1 cells over 28 days of
culture. Top panel: Ki-67 positive (green) proliferative cells. Second panel: Pan-Cytokeratin positive (yellow) PANC-1 cells. Third panel: CD-24 positive (yellow)
PANC-1 cells. Bottom panel: Collagen I secretion (yellow) by the PANC-1 cells. Cell nuclei in all images were stained with DAPI (blue). Scale bar = 100 µm.
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(Figure 5, bottom panel). Overall, these results highlight that in
our FN-coated inner scaffold PANC-1 cancer cells (tumor zone)
remain viable, are proliferative and secrete COL throughout the
culture period of 28 days.
Collagen I-Coated PU Outer Compartment of the
Hybrid Scaffold (Containing HMEC Endothelial and
PS-1 Stellate Cells)
Similar to independently studying the inner cylinder of the
hybrid scaffold [section “Fibronectin-Coated PU Inner Cylinder
Compartment of the Hybrid Scaffold (Containing PANC-1
Cells),” Figure 5] the outer cuboid scaffold consisting of PS-1
and HMEC cells (i.e., recapitulating the stromal compartment
of the TME) was independently studied for 35 days (see also
Figure 1 and section “Scaffold-Based Zonal 3D Cell Culture”).
More specifically, three different ratios of PS-1 and HMEC
cells were assessed to study the effect of seeding densities
on the evolution of different cells (see also section “Scaffold-
Based Zonal 3D Cell Culture”). As previously described [section
“Fibronectin-Coated PU Inner Cylinder Compartment of the
Hybrid Scaffold (Containing PANC-1 Cells)”], the cellular
morphology, cell proliferation, ECM secretion, and cell-specific
marker expressions were assessed at regular intervals. As shown
in Figure 6, Ki-67 positive proliferative cells were present within
the outer scaffold throughout the entire culture period (35 days).
Furthermore, at the beginning of the culturing period (day 7), a
clear distinction between the different ratios is observed in terms
of cell number, i.e., higher seeding density of the HMEC and
PS-1 cells showed more proliferating cells. However, by day 21,
all three cell ratios under study show a high cell number and
a uniform cellular distribution within the scaffolds. However,
the number of proliferative cells decreased toward the end of
the experimental time (day 35) for all three seeding ratios
assessed (Figure 6).
Cell-specific immunostaining for phenotypic markers was
carried out to identify the density and spatial distribution of PS-
1 (αSMA) and HMEC (CD-31) cells within the outer cuboid
scaffold. Figure 7 shows representative images immunostaining
for cell specific markers.
As can be seen in Figure 7, on day 7, the experimental systems
with equal number of PS-1 and HMEC cells (Figure 7, top
and middle panels) showed relatively similar distribution of the
two cell types, while the presence of excess PS-1 in the third
experimental system (Figure 7, bottom panel) resulted in the
stellate cells growing significantly and suppressing the growth
of the HMEC endothelial cells. On day 21 (week 3), all three
conditions showed a high number of PS-1 stellate cells. HMEC
endothelial cells were mainly visible in conditions with equal ratio
of PS-1 and HMEC, although their cell number was generally
lower than the PS-1 cells. For the 2:9 (PS-1:HMEC) ratio, similar
to day 7, CD-31 positive HMEC cells were not very visible
within the co-culture (Supplementary Figure S1). The αSMA-
staining also showed fiber-like structure and an aligned nature
of the activated stellate cells within the scaffolds, especially for
the experiment with abundance of PS-1, i.e., 2:9 ratio. Toward
the end of the culture period, at days 28 and 35 (weeks 4 and 5),
although cells were present within the scaffolds, their numbers
decreased. Furthermore, the morphology of the cells (particularly
the stellate cells) changed and loss of cell-specific markers (CD-31
and αSMA) was observed (Figure 7).
Activated pancreatic stellate cells are known to secrete
extensive ECM proteins (primarily COL), resulting as previously
described, in desmoplasia/fibrosis (Apte et al., 2004; Armstrong
et al., 2004; McCarroll et al., 2014). Hence, immunostaining
for human-specific COL was carried out for the outer
cuboid scaffold.
Excessive COL secretion was observed within our outer
cuboid scaffold (Figure 8). On day 7, the amount of COL was
directly proportional to the number of stellate cells, i.e., higher
number of PS-1 resulted in higher amount of COL secretion.
For all three conditions, COL secretion increased with time in
the early days of the culture (up to day 28). Similar to the cell-
specific marker expressions, toward the end of the culture period,
a decrease in COL amount was observed (day 35).
Complete, Hybrid, Zonal, Multi-Compartmental,
Multicellular Model of PDAC Containing Cancer Cells
(PANC-1), Endothelial Cells (HMEC), and Stellate
Cells (PS-1)
As reported in Sections “Fibronectin-Coated PU Inner Cylinder
Compartment of the Hybrid Scaffold (Containing PANC-1
Cells)” and “Collagen I-Coated PU Outer Compartment of
the Hybrid Scaffold (Containing HMEC Endothelial and PS-
1 Stellate Cells),” both the inner and outer scaffolds of our
hybrid model were individually viable for the entire duration
of the experiment, i.e., 28 days for the inner scaffold and
35 days for outer scaffold. All three cell types remained in a
proliferative state (Figures 5, 6), expressed cell-specific markers
(Figures 5, 7), and produced their own COL matrix protein
(Figures 5, 8). Thereafter, a multicellular PDAC in vitro model
was developed by assembling the inner and outer compartments
(section “Scaffold-Based Zonal 3D Cell Culture”) to obtain
a hybrid, zonal, tri-culture PDAC model containing PANC-1
cancer cells, HMEC endothelial cells, and PS-1 stellate cells
(for more details, see section “Scaffold-Based Zonal 3D Cell
Culture” and Figure 1). As per the experiments of the separate
scaffold compartments [sections “Fibronectin-Coated PU Inner
Cylinder Compartment of the Hybrid Scaffold (Containing
PANC-1 Cells)” and “Collagen I-Coated PU Outer Compartment
of the Hybrid Scaffold (Containing HMEC Endothelial and
PS-1 Stellate Cells)”] the cell proliferation, cell-specific marker
expression (pan-Cytokeratin, CD-31, and αSMA), and COL
secretion in the hybrid scaffold were monitored regularly.
As can be seen in Figure 9, Ki-67 positive proliferative
cells were visible in the hybrid scaffold throughout the entire
experimental time period, both in the inner and outer scaffold
for all seeding ratios (Figure 9). On day 21, outer and inner rings
were separately visible (Figure 9, first vertical panel). However,
for later time points (i.e., days 28 and 35), the two sections
of the scaffolds could not be easily distinguished, especially
for the conditions with higher cell numbers, indicating the
homogeneous merging of the two compartments (Figure 9).
As can be seen in Figure 10, for the cell specific phenotypic
markers expression, at day 21 (2 weeks post-assembling the
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FIGURE 6 | Representative immunofluorescence CLSM images of collagen I-coated PU outer cuboid compartment of the hybrid scaffold with Ki-67 positive (green)
proliferative PS-1 and HMEC cells over 35 days of culture. Top panel: PS-1:HMEC = 1:1 (PS-1 = 0.25 × 106 cells, HMEC = 0.25 × 106 cells), Middle panel:
PS-1:HMEC = 2:2 (PS-1 = 0.5 × 106 cells, HMEC = 0.5 × 106 cells), Bottom panel: PS1:HMEC = 9:2 (PS-1 = 2.25 × 106 cells, HMEC = 0.5 × 106 cells). Nuclei
for all images were stained with DAPI (blue). Scale bar = 100 µm.
hybrid model), all three cell types expressed their specific
markers. More specifically, pan-Cytokeratin positive PANC-
1 cells were visible within the FN-coated inner cylinder
compartment, while an abundance of αSMA positive PS-1 stellate
cells was observed in the collagen-coated outer cuboid scaffold
compartment. Parallel alignment of the stellate cells was visible
for all three seeding densities. CD-31 positive HMEC endothelial
cells were present within the dense stellate-cell-rich compartment
for all three cell ratios under study (indicated with red arrows in
Figure 10), but they were more visible in the experiments where
PS-1 and HMEC were in equal numbers (1:1:1 and 1:2:2 hybrid
scaffolds). Similar to the experiments of the independent outer
cuboid scaffold (Figure 7), changes in cellular morphology and
loss of cellular markers were observed on day 28 and were further
enhanced at the end of the culture period (day 35).
As mentioned earlier, the fibrotic reaction and the presence
of excessive ECM protein (desmoplasia) are hallmarks for
PDAC. Hence, COL secretion by the different cells was assessed
within our zonal multicellular model (Figure 11). Similar to
the separate experiments for the inner and outer scaffold
compartments (Figures 5, 8), at the beginning of the culture
(day 21), cancer cells in the inner scaffold compartment showed
very little COL secretion, while the stellate cells in the outer
scaffold compartment showed extensive COL protein production
(Figure 11, left panel). As time progressed, more COL secretion
was observed by both the PS-1 cells and the PANC-1 cells.
At the end of the 35 days (Figure 11, right panel), a slight
decrease in COL in the model was observed, in alignment with
the loss of cellular marker expressions and the morphology
changes (Figure 10).
Cellular migration and cellular interactions between the tumor
and the stromal cells within a cancer niche are important
aspects for cancer metastasis (Keleg et al., 2003; Xu et al., 2010).
As our hybrid multicellular model consists of two different
scaffold zones/compartments, the ability of the cells, especially
the PANC-1 cancer cells to migrate from one compartment
to the other is an important requirement for the physiological
relevance of the model. As observed in Figure 12, at day
21 (2 weeks post-assembly of the hybrid scaffold), cellular
migration was observed for all three cell ratios under study.
More specifically, for the 1:1:1 hybrid model (Figure 12, left
panel), PANC-1 cells (yellow arrows in Figure 12) migrated
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FIGURE 7 | Representative immunofluorescence CLSM images of collagen I-coated PU outer cuboid scaffold compartment of the hybrid scaffold with HMEC
(CD-31, red) and PS-1 (αSMA, green) cell distribution over 35 days of culture. Top panel: PS-1:HMEC = 1:1 (PS-1 = 0.25 × 106 cells, HMEC = 0.25 × 106 cells),
Middle panel: PS-1:HMEC = 2:2 (PS-1 = 0.5 × 106 cells, HMEC = 0.5 × 106 cells), Bottom panel: PS-1:HMEC = 9:2 (PS-1 = 2.25 × 106 cells,
HMEC = 0.5 × 106 cells). Nuclei for all images were stained with DAPI (blue). Endothelial cells are pointed with red arrow. Scale bar = 100 µm.
from the inner to the outer scaffold compartment containing
stellate and endothelial cells while the PS-1 stellate cells (green
arrows in Figure 12) bridge the two zones. HMEC (red arrow)
migration was also observed. For the 1:2:2 (Figure 12, middle
panel) and 1:2:9 (Figure 12, right panel) cell ratios in the
hybrid scaffolds, all three cell types (yellow, green, and red)
are observed together primarily at the junction of the two
scaffold compartments.
Overall, our results show the successful development of a
novel hybrid, zonal, multicellular scaffold-based PDAC in vitro
model containing pancreatic cancer, stellate, and endothelial
cells. The model was successfully maintained in culture for a total
of 35 days (5 weeks), although cellular/culture aging was observed
after 28 days (4 weeks).
DISCUSSION
Overall, in this work, we developed, characterized, and
maintained long-term (35-day) novel PU scaffold-based,
multicellular, in vitro models of pancreatic cancer consisting
of pancreatic cancer (PANC-1), stellate (PS-1), and
endothelial (HMEC) cells.
Single Homogeneous Scaffold-Based
Multicellular Model of PDAC
Our novel PU scaffold-based in vitro PDAC model was able to
maintain cell viability and expression of cell specific markers
for 28 days (4 weeks) in both FN- and COL-coated PU
scaffolds for all co- and tri-cultures under study (Figures 3, 4).
Different cell types showed growth, which was dependent
on the type of ECM proteins used to coat the scaffolds.
More specifically, the presence of FN enhanced the growth
of cancer cells (PANC-1) within the multicellular systems
(co-culture and tri-culture), while COL assisted in a more
even distribution and higher number of stellate (PS-1) and
endothelial (HMEC) cells (Figure 4). It is worth noting that
previous published research, wherein such multicellular models
consisting of cancer, endothelial, and stellate/fibroblast cells
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FIGURE 8 | Representative immunofluorescence CLSM images of collagen I (rat tail)-coated PU outer cuboid compartment of the hybrid scaffold for human specific
collagen I secretion (yellow) over 35 days of culture. Top panel: PS-1:HMEC = 1:1 (PS-1 = 0.25 × 106 cells, HMEC = 0.25 × 106 cells), Middle panel:
PS-1:HMEC = 2:2 (PS-1 = 0.5 × 106 cells, HMEC = 0.5 × 106 cells), Bottom panel: PS-1:HMEC = 9:2 (PS-1 = 2.25 × 106 cells, HMEC = 0.5 × 106 cells). Nuclei
for all images were stained with DAPI (blue). Scale bar = 100 µm.
were attempted, a depletion of the supporting cells (endothelial
and fibroblast/stellate) was observed at a very early stage of
culture (day 4) (Di Maggio et al., 2016; Lazzari et al., 2018).
In contrast, our polymer scaffold-based model was successful
in maintaining the complex multicellular model of PDAC for
28 days (4 weeks).
Novel Hybrid, PU Scaffold-Based
Multicellular PDAC Model
Based on our observations above (section “Single Homogeneous
Scaffold-Based Multicellular Model of PDAC”), it was evident
that different cell types within the tumor niche prefer different
ECM proteins for high growth and survival. Hence, to account
for this, we designed a novel hybrid, multi-compartmental
multicellular model consisting of (i) an external/outer collagen-
coated cuboid compartment for growth of the stromal cells, i.e.,
stellate and endothelial cells, and (ii) an internal/inner FN-coated
cylindrical compartment for growth of the pancreatic cancer cells
(Figure 1). We observed cell growth and proliferation (Figure 9),
presence of cell-specific markers (Figure 10), the production of
COL (Figure 11), as well as cell migration (Figure 12) within
our novel hybrid model over a period of 35 days (5 weeks).
Previous studies focusing on multicellular, in vitro models of
pancreatic cancers have all been spheroids/cell aggregate based
and were maintained in culture for a relatively short time
period, i.e., between 24 h and 7 days (Froeling et al., 2009; Di
Maggio et al., 2016; Ware et al., 2016; Lazzari et al., 2018).
To the best of our knowledge, we report here for the first
time, a long-term (35-day) PU scaffold-based, hybrid, zonal,
multicellular (cancer, stellate, and endothelial cells) model of the
PDAC tumor niche.
Characterization of Separate Inner (PANC-1) and
Outer Compartment (HMEC, PS-1) Compartments of
the Hybrid Scaffold
Prior to the development of the hybrid zonal scaffold, we studied
independently the two scaffold compartments of the hybrid
scaffold to monitor long term the evolution of the three different
cell types (Figure 1).
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FIGURE 9 | Representative immunofluorescence CLSM images for Ki-67 positive (green) proliferative cells within the complete multicellular hybrid scaffold,
containing both the collagen I-coated outer cuboid and the fibronectin-coated inner cylinder, over 35 days of culture. Top panel: PANC-1:HMEC:PS-1 = 1:1:1
(PANC-1 = 0.25 × 106 cells, PS-1 = 0.25 × 106 cells, HMEC = 0.25 × 106 cells), Middle panel: PANC-1:HMEC:PS-1 = 1:2:2 (PANC-1 = 0.25 × 106 cells,
PS-1 = 0.5 × 106 cells, HMEC = 0.5 × 106 cells), Bottom panel: PANC-1:HMEC:PS-1 = 1:2:9 (PANC-1 = 0.25 × 106 cells, PS-1 = 2.25 × 106 cells,
HMEC = 0.5 × 106 cells). Nuclei for all images were stained with DAPI (blue). Scale bar = 100 µm.
Inner fibronectin-coated cylinder scaffold compartment
(PANC-1 cells)
We have previously demonstrated that PANC-1 cancer cells
prefer FN-coated PU scaffolds for long-term cell proliferation
and for mimicking various in vivo characteristics like COL
production, realistic hypoxic gradients, and treatment resistance
(Totti et al., 2018; Gupta et al., 2019). Hence, we cultured PANC-
1 cancer cells on FN-coated cylindrical PU scaffolds for 28 days
[see also sections “Scaffold-Based Zonal 3D Cell Culture” and
“Fibronectin-Coated PU Inner Cylinder Compartment of the
Hybrid Scaffold (Containing PANC-1 Cells)”].
As shown in Figure 5, PANC-1 cancer cells were able to
proliferate within the FN-coated cylinder scaffold compartment
for the entire duration of the experiment. We also monitored
the secretion of COL as it is an important feature of the
PDAC TME in vivo (Apte et al., 2004; Armstrong et al., 2004;
Shintani et al., 2006; Shields et al., 2011). We observed COL
production by the PANC-1 cancer cells as early as 14 days
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FIGURE 10 | Representative immunofluorescence CLSM images showing the cellular distribution of PANC-1 (pan-Cytokeratin, yellow), HMEC (CD-31, red), and
PS-1 (αSMA, green) within the complete hybrid scaffold containing both the collagen I-coated outer cuboid and the fibronectin-coated inner cylinder, over 35 days of
culture. Top panel: PANC-1:HMEC:PS-1 = 1:1:1 (PANC-1 = 0.25 × 106 cells, PS-1 = 0.25 × 106 cells, HMEC = 0.25 × 106 cells), Middle panel:
PANC-1:HMEC:PS- = 1:2:2 (PANC-1 = 0.25 × 106 cells, PS-1 = 0.5 × 106 cells, HMEC = 0.5 × 106 cells), Bottom panel: PANC-1:HMEC:PS-1 = 1:2:9
(PANC-1 = 0.25 × 106 cells, PS-1 = 2.25 × 106 cells, HMEC = 0.5 × 106 cells). Nuclei for all images were stained with DAPI (blue). Endothelial cells are pointed with
red arrow. Scale bar = 100 µm.
post-cell seeding, which increased throughout the culture period
(Figure 5). These observations are in agreement to our previously
published monocellular model of PDAC on FN-coated PU cubic
scaffolds (Totti et al., 2018). Furthermore, with respect to the
upregulation of cell-specific markers, PANC-1 cells contained a
heterogeneous mixture of cells positive for both pan-Cytokeratin
and CD-24 throughout the entire culture period (Figure 5),
indicating that the PANC-1 cells were able to maintain their
neoplastic characteristics long term.
Outer collagen-coated cuboid compartment (PS-1, HMEC
cells)
As observed in the mono-culture study (Figure 2A), HMEC
endothelial cells preferred COL-coated scaffolds over uncoated
or FN-coated ones. This is in agreement to previously published
literature, wherein endothelial cells’ preference for COL matrix
over other materials, like alginate and fibrin, has been reported
(Rioja et al., 2016; Nguyen et al., 2017). PS-1 stellate cells showed
a preference for coated scaffolds over those uncoated (Figure 2B)
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FIGURE 11 | Representative immunofluorescence CLSM images showing collagen I (human) ECM protein secretion within the complete multicellular hybrid scaffold
containing both the collagen I (rat tail)-coated outer cuboid and the fibronectin-coated inner cylinder, over 35 days of culture. Top panel:
PANC-1:HMEC:PS-1 = 1:1:1 (PANC-1 = 0.25 × 106 cells, PS-1 = 0.25 × 106 cells, HMEC = 0.25 × 106 cells), Middle panel: PANC-1:HMEC:PS-1 = 1:2:2
(PANC-1 = 0.25 × 106 cells, PS-1 = 0.5 × 106 cells, HMEC = 0.5 × 106 cells), Bottom panel: PANC-1:HMEC:PS-1 = 1:2:9 (PANC-1 = 0.25 × 106 cells,
PS-1 = 2.25 × 106 cells, HMEC = 0.5 × 106 cells). Nuclei for all images were stained with DAPI (blue). Scale bar = 100 µm.
but did not show any specific preference for either COL or
FN. Froeling et al. (2009) have reported a similar observation
wherein PS-1 cells grew similarly in presence of collagen, FN,
and Matrigel. Therefore, COL was selected to coat the external
stromal compartment of the hybrid scaffolds. As described in
Section “Scaffold-Based Zonal 3D Cell Culture,” three different
rations of stellate and endothelial cells were studied. Ki-67
positive proliferative cells were present in all three cell ratios
under study (1:1, 2:2, and 2:9; HMEC:PS-1) throughout the entire
culture period (35 days). However, we observed a decrease in
the total cell number toward the end of the culture period, i.e.,
from day 28 days onward (Figure 6). As observed in Figure 7,
for the 1:1 and 2:2 cell ratios (i.e., the conditions with equal
number of HMEC and PS-1 cells), both HMEC and PS-1 cell
were present within the PU scaffolds. PS-1 stellate cells had
aligned fibril cellular morphology, which supports their active
state (Bachem et al., 1998; Masamune et al., 2003). CD-31 positive
HMEC cells were visible within the PS-1 fibrous stroma. These
cellular markers and close interactions between PS-1 and HMEC
cells were clearly observed until day 21 of culture. However,
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FIGURE 12 | Representative immunofluorescence CLSM image of the hybrid scaffold demonstrating cellular migration of PANC-1 (pan-Cytokeratin, yellow), HMEC
(CD-31, red), and PS-1 (αSMA, green) at day 21 (2 weeks post-assembly of hybrid scaffold) between the inner and the outer scaffold compartments. Left panel:
PANC-1:HMEC:PS-1 = 1:1:1 (PANC-1 = 0.25 × 106 cells, PS-1 = 0.25 × 106 cells, HMEC = 0.25 × 106 cells), Middle panel: PANC-1:HMEC:PS-1 = 1:2:2
(PANC-1 = 0.25 × 106 cells, PS-1 = 0.5 × 106 cells, HMEC = 0.5 × 106 cells), Right panel: PANC-1:HMEC:PS-1 = 1:2:9 (PANC-1 = 0.25 × 106 cells,
PS-1 = 2.25 × 106 cells, HMEC = 0.5 × 106 cells). Nuclei for all images were stained with DAPI (blue). Migration shown by cell-specific arrow: PANC-1 = yellow,
PS-1 = green, HMEC = red. Scale bar = 100 µm.
on day 28 and beyond, we observed changes in the cellular
morphology of the PS-1 cells, i.e., a loss of their fibril-like
structure (Figure 7). We also observed a decrease in cell number,
loss of cell-specific markers, and a separation of the two cell
types, which could be attributed to the natural aging of the cells.
We have previously observed a similar cellular aging within our
mono-culture model (PANC-1 cells only), wherein a decrease
in cell number was seen after 28 days of culture (Gupta et al.,
2019). However, it is difficult to compare our observations with
existing literature as, to the best of our knowledge, there are
no similar long-term (35-day) studies. For the 2:9 cell ratio,
wherein an abundance of PS-1 stellate cells were present, the
fibrous cellular morphology of the stellate cells was observed
as early as day 7 (Figure 7). Due to the abundance of stellate
cells, the growth of HMEC endothelial cells was reduced within
this system, and a relatively low number CD-31 positive cells
were observed (Figure 7). Overall, we did not observe any
sprouting and vessel formation within our co-culture, which may
suggest a need for more specialized media containing growth
factors promoting angiogenesis like VEGF, or those found in
Matrigel, to promote structured angiogenesis (Gerhardt et al.,
2003; Son et al., 2006; Eichmann and Simons, 2012; Siemerink
et al., 2012; Yin et al., 2018). It should be highlighted that
although we observed some degree of cellular aging from day
28 (4 weeks) onward, both cell types (HMEC and PS-1) were
present within our COL-coated PU cuboid scaffold compartment
for 35 days (Figure 7), which is significantly longer than currently
reported co-cultures of stellate cells and endothelial cells (Di
Maggio et al., 2016). More specifically, Di Maggio et al. (2016)
developed a hydrogel-based system consisting of Matrigel and
COL, wherein co-culture of PS-1 stellate cells and HUVECs,
as well as the effects of PS-1 stellate cells on HUVECs, were
assessed for 96 h. In that system, the presence of stellate cells
along with collagen and Matrigel assisted in endothelial cell
sprouting and the formation of a luminal structure. Generally,
activated pancreatic stellate cells have been well-established to
be the key element behind the ECM-rich (primarily COL),
fibrotic/desmoplastic TME of pancreatic cancer (Apte et al.,
2012; Suklabaidya et al., 2018). To assess the PS-1 stellate cells’
capability of mimicking this desmoplastic feature in our system,
human-specific COL immunostaining was carried out. High
amounts of COL were observed within our outer cuboid scaffold
compartment for all three cell ratios under study (Figure 8).
Furthermore, COL showed aligned structures (Figure 8), which
are known to support/promote metastasis of pancreatic cancer
cells (Drifka et al., 2016). Thus, we demonstrated successfully the
development and long-term (35-day) maintenance of endothelial
and stellate cells scaffold-assisted co-culture, which can act as
a “supporting” compartment for our novel hybrid tri-culture
model of PDAC. To the best of our knowledge, this is the longest
reported co-culture of stellate cells and endothelial cells in a 3D
in vitro model.
Characterization of Hybrid, Scaffold-Assisted
Multicellular Model of PDAC
Following the assessments of the independent inner and outer
scaffold compartments, the complete hybrid zonal in vitro model
of PDAC was assembled and studied. Very few studies are
available for multicellular in vitro models of PDAC involving
cancer cells, endothelial cells, and stellate/fibroblast cells to mimic
the fibrosis, and all of these studies were carried out for a
relatively short period of time (24 h to 7 days). For example,
Beckermann et al. (2008) cultured a multicellular model of
PDAC involving MIA PaCa-2 pancreatic cancer cells, primary
fibroblasts, and HUVECs in a spheroid system for 24 h. Similarly,
Lazzari et al. (2018) developed a multicellular spheroid-based
model of PANC-1 cancer cells, MRC-5 fibroblasts, and HUVECs
and assessed the effects of chemotherapeutic agents (gemcitabine
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and doxorubicin) within it. The model was viable for 4 days,
beyond which loss of HUVECs and MRC-5 fibroblasts was
observed. Di Maggio et al. (2016) developed a hydrogel-based
tri-culture of PDAC with cancer cells (Capan-1, AsPC-1, and
COLO-357), HUVECs, and stellate cells (PS-1). The system was
cultured for 7 days. A significant decrease in the number of
endothelial cells (HUVECs) in the developed hydrogel-based
tri-culture system was observed after 72 h. In contrast to the
currently reported spheroid-based studies, our hybrid, PU highly
porous scaffold-based, zonal model of PDAC was able to support
all three cell types for a total of 35 days (5 weeks) making it
the longest reported in vitro model of PDAC. Further studies
to elucidate the reasons behind the progressive loss of the
supporting cells (endothelial and stellate cells) in 3D models
would be informative.
As previously described, our novel hybrid scaffold-based
multicellular model was characterized via immunostaining and
CLSM imaging to assess cell growth and proliferation, ECM
protein secretion and maintenance of cellular morphology
and phenotypic characteristics (Figures 9–11). We have
successfully demonstrated that our hybrid scaffold could
maintain proliferating cells (Figure 9) expressing cell-specific
markers (Figure 10) throughout the entire culture period
(35 days). Furthermore, our model showed extensive COL
secretion by the stellate cells and even the cancer cells to
some extent, indicating its ability to mimic in vitro the PDAC
desmoplastic nature (Figure 11). This fibrotic desmoplastic
nature of PDAC is a key reason behind the resistance of
pancreatic cancer to currently available therapeutic methods;
therefore, recapitulating it in vitro is key for more accurate
treatment screening trials (Chand et al., 2016; Bynigeri et al.,
2017; Ansari et al., 2018). We also observed cellular migration
across the two zones by all three cell types, highlighting that
the cells are able to overcome the physical barrier of being in
two separate scaffolds zones (Figure 12). Cellular migration
by the cancer cells and the stromal cells, along with cross-talk
between them has been linked with PDAC metastasis (Keleg
et al., 2003; Xu et al., 2010; Tuveson and Neoptolemos, 2012;
Zhan et al., 2017). Hence, this characteristic of our model
can be exploited to study the metastatic properties of PDAC.
In terms of total cell numbers in our hybrid scaffolds, as
expected, differences were observed for different seeding ratios.
Nonetheless, the different seeding ratios of the three cell types
all showed similar characteristics in terms of cell proliferation
(Figure 9), expression of phenotypic markers (Figure 10), and
COL production (Figure 11). The choice of seeding density for
future work would depend on the specific aim of the work. For
example, if the aim would be to study the effect of desmoplasia,
then high number of stellate cells (1:2:9 ratio) would be an ideal
choice; however, if the aim would be to study more in depth
the interactions between the different cell types, conditions
with equal number of stellate and endothelial cells would be
more appropriate, promoting the presence of higher amounts of
endothelial cells. Furthermore, the availability of PDAC models
with different ratios of the cells involved is important to account
for tumor variability among patients and even intra-tumoral
variability for the same patient, since fibrotic intensity as well
as vascularization levels differ between patients (Junttila and De
Sauvage, 2013; Koay et al., 2016; Verbeke, 2016). Coupled with
the feasibility of maintaining a long-term robust culture, our
hybrid model’s ability to mimic desmoplasia and to account for
tumor/patient variability, highlights the possibility of using it to
(i) study the mechanisms behind PDAC’s therapeutic resistance,
(ii) assess the effects of therapeutic methods, both traditional
(chemo and radiotherapy) (Adcock et al., 2015; Kuen et al., 2017;
Al-Ramadan et al., 2018; Gupta et al., 2019) and novel (proton
therapy) (Hong et al., 2011, 2014; Terashima et al., 2012), (iii)
conduct fractionated radiation screening (Schellenberg et al.,
2008; Mahadevan et al., 2010; Loehrer et al., 2011), and (iv)
promote personalized treatment screening.
CONCLUSION
Overall in this study, we have developed and characterized a
novel PU scaffold-assisted multicellular hybrid in vitro model
of PDAC, with specific ECM protein-coated zones for the
tumor compartment and the stromal compartment. More
specifically, we have developed, characterized, and maintained
for a month a novel tri-culture of pancreatic cancer (PANC-
1), endothelial (HMEC), and stellate (PS-1) cells. The inner
compartment of the scaffold was FN-coated and contained cancer
cells, which were surrounded by an external collagen-coated
scaffold compartment consisting of stellate and endothelial
cells. Overall, such configuration enabled a more accurate
recapitulation of the zonal distribution of different cell types
of the pancreatic TME. The developed hybrid zonal model
was able to (i) support long-term growth and proliferation
of cancer (PANC-1), endothelial (HMEC), and stellate (PS-1)
cells for up to 35 days (5 weeks), (ii) allow the maintenance
of cell specific morphology and phenotypic markers, (iii)
form dense desmoplastic region through abundant sections of
COL protein, and (iv) demonstrate cellular migration between
the different zones. With the capability of mimicking several
key characteristics of the PDAC tumor (desmoplasia, cellular
migration), the model shows great potential for future use in a
range of applications from basic cancer studies to personalized
healthcare. Future work on this model will focus on (i) further
validation of the model’s robustness with patient samples, (ii)
assessment of the model’s capability to mimic the PDAC’s
treatment resistance, and (iii) incorporation of immune cells with
the help of perfusion bioreactor.
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